For the quarter ending 2025-12-26, DLB had -$65,795K decrease in cash & cash equivalents over the period. $50,171K in free cash flow.
| Cash Flow | 2025-12-26 | 2025-09-26 | 2025-06-27 |
|---|---|---|---|
| Revenue from contract with customer | - | 1,349,130 | - |
| Cost of revenue-Total Licensing Revenue | - | 83,619 | - |
| Cost of revenue-Products And Services | - | 76,513 | - |
| Research and development | - | 261,792 | - |
| Sales and marketing | - | 360,711 | - |
| General and administrative | - | 286,529 | - |
| Restructuring charges | - | 15,007 | - |
| Interest income/(expense), net | - | 15,376 | - |
| Other income, net | - | 23,150 | - |
| Provision for income taxes | - | 46,993 | - |
| Net income including noncontrolling interest | 53,681 | 49,654 | 206,838 |
| Depreciation and amortization | 24,145 | 21,998 | 65,829 |
| Stock-based compensation | 37,211 | 31,052 | 97,462 |
| Amortization of operating lease right-of-use assets | 2,668 | 2,577 | 8,193 |
| Amortization of premium on investments | - | 0 | 0 |
| Provision for credit losses | 792 | -148 | 2,582 |
| Deferred income taxes | 16 | 14,134 | -9,146 |
| Impairment loss on internally developed software | - | 0 | - |
| Share of net income of equity method investees, net of cash distributions | 5,276 | 707 | - |
| Other non-cash items affecting net income | 1,890 | -16,445 | 17,553 |
| Accounts receivable, net | 82,956 | 33,697 | -15,234 |
| Contract assets, net | 19,824 | -23,582 | 6,902 |
| Inventories | -879 | -3,999 | -4,020 |
| Operating lease right-of-use assets | 4,810 | 2,788 | 1,717 |
| Prepaid expenses and other assets | 3,152 | 31,749 | -46,972 |
| Accounts payable and accrued liabilities | 43,575 | 71,830 | -48,979 |
| Income taxes, net | 4,394 | -44,724 | 1,895 |
| Contract liabilities | 6,828 | -4,018 | -1,061 |
| Operating lease liabilities | 1,552 | -266 | -8,237 |
| Other non-current liabilities | -3,034 | 5,657 | -6,063 |
| Net cash provided by operating activities | 54,799 | 122,831 | 349,367 |
| Purchases of marketable securities | - | 0 | 0 |
| Proceeds from sales of marketable securities | - | 0 | 15,911 |
| Proceeds from maturities of available-for-sale securities | - | 0 | 0 |
| Proceeds from sale of assets | - | 0 | 16,881 |
| Proceeds from sale of intangible assets | 6,623 | - | - |
| Purchases of property, plant, and equipment | 4,628 | 16,244 | 20,104 |
| Business combinations, net of cash and restricted cash acquired, and other related payments | 0 | 0 | 1,362 |
| Purchases of intangible assets | 750 | 5,593 | - |
| Purchases of other investments | - | 75 | - |
| Net cash provided by/(used in) investing activities | 1,245 | -21,912 | 11,326 |
| Proceeds from issuance of common stock | 14,253 | 5,016 | 38,681 |
| Repurchase of common stock | 70,005 | 35,002 | 89,990 |
| Payment of cash dividend | 34,339 | 31,589 | 95,010 |
| Distributions to noncontrolling interest | 547 | 398 | 1,449 |
| Payment of excise tax on repurchase of common stock | - | 261 | - |
| Purchase of noncontrolling interest in business combinations | - | 0 | - |
| Equity issued in connection with business combination | - | 0 | - |
| Payment of excise tax on repurchase of common stock | - | - | 261 |
| Shares repurchased for tax withholdings on vesting of restricted stock | 31,196 | 2,082 | 35,154 |
| Equity issued in connection with business combination | - | - | 0 |
| Payments for deferred consideration | - | 0 | - |
| Net cash used in financing activities | -121,834 | -64,055 | -183,183 |
| Effect of foreign exchange rate changes on cash and cash equivalents | - | 1,235 | - |
| Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash | -1,307 | - | 1,302 |
| Net increase/(decrease) in cash, cash equivalents, and restricted cash | -65,795 | 36,797 | 178,812 |
| Cash and cash equivalents at beginning of period | 793,361 | 577,752 | - |
| Cash and cash equivalents at end of period | 727,566 | 793,361 | - |
Dolby Laboratories, Inc. (DLB)
Dolby Laboratories, Inc. (DLB)